Please use this identifier to cite or link to this item:
|Title:||Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.|
|Epworth Authors:||Kincaid-Smith, Priscilla|
|Other Authors:||Farish, Stephen|
Body Mass Index
Dose-Response Relationship, Drug
Administration & Dosage
Epworth HealthCare, Melbourne, Australia
|Citation:||Nephrology (Carlton). 2008 Feb;13(1):58-62|
|Abstract:||AIM: To investigate the effect of a thiazolidinedione on proteinuria in patients with non-diabetic renal disease. METHODS: In an open-label randomized cross-over study, 40 adults with chronic non-diabetic renal disease completed the study. In a random fashion, one group was treated for 4 months with 4 mg of rosiglitazone first followed by a 4-month period of standard treatment. The opposite order was used for the second group. RESULTS: Baseline urinary protein excretion rate was 1.45 g/24 h. On rosiglitazone, there was a drop of urinary protein level of 0.24 g/24 h (P=0.045). In contrast, there was a trend for proteinuria to increase during the control period (0.12 g/24 h, P=0.18). The urine protein level on rosiglitazone was lower than on usual treatment (0.36 g/24 h, P=0.002, 95% CI 0.15-0.58). There was a similar beneficial effect on systolic blood pressure which was reduced by rosiglitazone by 7.8 mmHg (P=0.006, 95% CI 2.6-13.1). Although average fasting glucose was only 5.8 mmol/L, there was a significant Spearman correlation between fasting glucose and a reduction in urinary protein levels (r=0.34, P=0.045). CONCLUSION: It is concluded that thiazolidinediones may have a role in the management of non-diabetic proteinuria of various aetiologies. In this study the average body mass index was 28.9 kg/m2. It will be important to repeat these studies in non-overweight subjects with non-diabetic proteinuria and in addition to trial maximal therapeutic doses of the thiazolidenedione.|
|Affiliated Organisations:||Faculty Education Unit, Faculty of Medicine, Dentistry and Health Sciences|
Department of Medicine, St Vincent's Hospital
Department of Medicine, Austin Health – Repatriation Hospital, Heidelberg, Victoria 3081, Australia.
University of Melbourne, Melbourne, Victoria, Australia
|Type of Clinical Study or Trial:||Crossover Design|
|Appears in Collections:||UroRenal, Vascular|
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.